This CPD activity is supported by an unrestricted education grant by Reckitt.[/caption]
Jess Hadley, community pharmacist and Professional Officer at PDL[/caption]
Peter Guthrey, Senior Pharmacist – Strategic Policy at PSA[/caption]
Professor Margie Danchin[/caption]
Dr Peter Tenni[/caption]
How should we deprescribe gabapentinoids, according to the Maudsley Deprescribing Guidelines[/caption]
6CPA program audits coming
Programs funded under the Sixth Community Pharmacy Agreement (6CPA) will be subject to audits from next week to detect any inaccurate or ineligible claims.
The...
Pain pointers: How to prepare your pharmacy for codeine change
Preparing now for the up‑scheduling of codeine‑containing medicines to prescription-only will mean pharmacists are in a better position to inform and educate their customers....
Realising pharmacists’ full potential
We are working to achieve the 11 key actions in Pharmacists in 2023 to unlock opportunities for pharmacists as the custodians of medicine safety.
I was...
Lack of evidence raises questions on long-term PPI use
There is rising concern over the side effects of long-term proton pump inhibitor (PPI) use but limited evidence to warrant discontinuation, a literature review...
New opioid patient resource
The balance between adequate pain relief and safety with opioids is now more achievable with the release of a handy new resource for patients...
Choosing wisely: sedatives
In the third of a six-part series, we expand on the PSA Choosing Wisely recommendations, taking a closer look at the use of sedatives....
